Abbott recombinant urokinase (correction)
Executive Summary
Abbott is currently conducting Phase III studies of recombinant urokinase in catheter clearance. The company expects to file an NDA in late 2003. "The Pink Sheet" (Oct. 14, p. 26) incorrectly stated that Abbokinase was undergoing the Phase III study...